BR9915985B1 - 2-cianopirrolidinas n-substituídas, composição farmacêutica que as compreende e uso das mesmas - Google Patents
2-cianopirrolidinas n-substituídas, composição farmacêutica que as compreende e uso das mesmas Download PDFInfo
- Publication number
- BR9915985B1 BR9915985B1 BRPI9915985-6A BR9915985A BR9915985B1 BR 9915985 B1 BR9915985 B1 BR 9915985B1 BR 9915985 A BR9915985 A BR 9915985A BR 9915985 B1 BR9915985 B1 BR 9915985B1
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compound
- formula
- acid addition
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical class N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 59
- 150000003839 salts Chemical group 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 25
- -1 3-hydroxy-1-adamantyl Chemical group 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 238000007792 addition Methods 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000460 chlorine Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- DWPIPTNBOVJYAD-UHFFFAOYSA-N 3-aminoadamantan-1-ol Chemical compound C1C(C2)CC3CC1(N)CC2(O)C3 DWPIPTNBOVJYAD-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000006362 insulin response pathway Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- XDOMURQNGATABE-UHFFFAOYSA-N 1-(2-aminoacetyl)pyrrolidine-2-carbonitrile Chemical group NCC(=O)N1CCCC1C#N XDOMURQNGATABE-UHFFFAOYSA-N 0.000 description 2
- FMDGXCSMDZMDHZ-UHFFFAOYSA-N 1-isocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1 FMDGXCSMDZMDHZ-UHFFFAOYSA-N 0.000 description 2
- XLURSORWGOXQCP-UHFFFAOYSA-N 3-methoxyadamantan-1-amine Chemical compound C1C(C2)CC3CC2(N)CC1(OC)C3 XLURSORWGOXQCP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 229910052740 iodine Chemical group 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- ZZSWEEPJPCTZEI-UHFFFAOYSA-N (3-amino-1-adamantyl) acetate Chemical compound C1C(C2)CC3CC2(N)CC1(OC(=O)C)C3 ZZSWEEPJPCTZEI-UHFFFAOYSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- HMPCLMSUNVOZLH-ALPUWHEMSA-N (3s,5r)-4-aminoadamantan-1-ol Chemical compound C1C(C2)C[C@H]3C(N)[C@@H]1CC2(O)C3 HMPCLMSUNVOZLH-ALPUWHEMSA-N 0.000 description 1
- ZHUTVLURGLOKMO-UHFFFAOYSA-N 1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCCC1C#N ZHUTVLURGLOKMO-UHFFFAOYSA-N 0.000 description 1
- KAUMSDCJVYEECC-UHFFFAOYSA-N 1-aminoadamantan-2-ol Chemical compound C1C(C2)CC3CC2C(O)C1(N)C3 KAUMSDCJVYEECC-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- AKPWQXXITUXNMB-UHFFFAOYSA-N 3-ethoxyadamantan-1-amine Chemical compound C1C(C2)CC3CC2(N)CC1(OCC)C3 AKPWQXXITUXNMB-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical class CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101100439111 Rattus norvegicus Cebpd gene Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- VLLNJDMHDJRNFK-UHFFFAOYSA-N adamantan-1-ol Chemical compound C1C(C2)CC3CC2CC1(O)C3 VLLNJDMHDJRNFK-UHFFFAOYSA-N 0.000 description 1
- QZWNXXINFABALM-UHFFFAOYSA-N adamantan-2-amine Chemical compound C1C(C2)CC3CC1C(N)C2C3 QZWNXXINFABALM-UHFFFAOYSA-N 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002933 immunoreactive insulin Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- AFOBJKRQKYUWGQ-UHFFFAOYSA-N n-benzyl-3-hydroxyadamantane-1-carboxamide Chemical compound C1C(O)(C2)CC(C3)CC1CC32C(=O)NCC1=CC=CC=C1 AFOBJKRQKYUWGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20906898A | 1998-12-10 | 1998-12-10 | |
US09/209,068 | 1998-12-10 | ||
PCT/EP1999/009708 WO2000034241A1 (en) | 1998-12-10 | 1999-12-09 | N-substituted 2-cyanopyrrolidines |
Publications (3)
Publication Number | Publication Date |
---|---|
BR9915985A BR9915985A (pt) | 2001-09-04 |
BR9915985B1 true BR9915985B1 (pt) | 2014-03-18 |
BRPI9915985B8 BRPI9915985B8 (pt) | 2021-05-25 |
Family
ID=22777194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9915985A BRPI9915985B8 (pt) | 1998-12-10 | 1999-12-09 | 2-cianopirrolidinas n-substituídas, composição farmacêutica que as compreende e uso das mesmas |
Country Status (34)
Country | Link |
---|---|
US (1) | US6166063A (pt) |
EP (1) | EP1137635B1 (pt) |
JP (2) | JP3681110B2 (pt) |
KR (2) | KR100509311B1 (pt) |
CN (1) | CN1160330C (pt) |
AR (1) | AR023719A1 (pt) |
AT (1) | ATE307112T1 (pt) |
BR (1) | BRPI9915985B8 (pt) |
CA (1) | CA2350609C (pt) |
CO (1) | CO5150173A1 (pt) |
CY (3) | CY1105355T1 (pt) |
CZ (1) | CZ299151B6 (pt) |
DE (3) | DE122008000017I1 (pt) |
DK (1) | DK1137635T3 (pt) |
ES (1) | ES2251847T3 (pt) |
FR (1) | FR08C0005I2 (pt) |
HK (1) | HK1040394B (pt) |
HU (1) | HU226769B1 (pt) |
ID (1) | ID28796A (pt) |
IL (2) | IL143091A0 (pt) |
LU (2) | LU91409I2 (pt) |
MY (1) | MY123244A (pt) |
NL (2) | NL300333I2 (pt) |
NO (3) | NO318741B1 (pt) |
NZ (1) | NZ511935A (pt) |
PE (1) | PE20001317A1 (pt) |
PL (1) | PL199443B1 (pt) |
RU (1) | RU2251544C2 (pt) |
SK (1) | SK286635B6 (pt) |
TR (1) | TR200101478T2 (pt) |
TW (1) | TW509674B (pt) |
UY (1) | UY25843A1 (pt) |
WO (1) | WO2000034241A1 (pt) |
ZA (1) | ZA200104581B (pt) |
Families Citing this family (303)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2344246A1 (en) * | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
DE19940130A1 (de) * | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
US20040152745A1 (en) * | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
AU1916401A (en) * | 1999-11-12 | 2001-06-06 | Guilford Pharmaceuticals Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
SG149676A1 (en) * | 1999-12-23 | 2009-02-27 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
ATE346613T1 (de) | 2000-01-21 | 2006-12-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
US20080076811A1 (en) * | 2000-01-21 | 2008-03-27 | Bork Balkan | Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents |
AU2001228309A1 (en) * | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AU2001268958B2 (en) | 2000-07-04 | 2006-03-09 | Novo Nordisk A/S | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
EP1326630B1 (en) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Use of glp-2 peptides |
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
AU9419701A (en) * | 2000-10-06 | 2002-04-22 | Tanabe Seiyaku Co | Aliphatic nitrogenous five-membered ring compounds |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
UA74023C2 (en) * | 2000-11-10 | 2005-10-17 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
EP1354882A1 (en) * | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
US20030060494A1 (en) * | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
ATE370943T1 (de) * | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
EP1399420B1 (en) | 2001-06-27 | 2007-12-05 | SmithKline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
US6709651B2 (en) * | 2001-07-03 | 2004-03-23 | B.M.R.A. Corporation B.V. | Treatment of substance P-related disorders |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
CA2464995A1 (en) * | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
US20050101638A1 (en) * | 2002-11-08 | 2005-05-12 | Webb Randy L. | Combination of organic compounds |
US20030135663A1 (en) * | 2002-01-16 | 2003-07-17 | Sun Microsystems, Inc. | Method, system, and program for including device parameters from a device driver in a configuration file |
BR0307665A (pt) | 2002-02-13 | 2005-01-04 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos |
CN1308311C (zh) | 2002-02-13 | 2007-04-04 | 霍夫曼-拉罗奇有限公司 | 新型吡啶-和喹啉-衍生物 |
US7074798B2 (en) | 2002-02-25 | 2006-07-11 | Eisai Co., Ltd | Xanthine derivative and DPPIV inhibitor |
WO2003082817A2 (en) * | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
MXPA04012149A (es) * | 2002-06-03 | 2005-04-19 | Novartis Ag | El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas. |
US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
JP2004026678A (ja) * | 2002-06-24 | 2004-01-29 | Microbial Chem Res Found | 2型糖尿病治療剤 |
AU2003248259A1 (en) * | 2002-07-10 | 2004-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel azetidine derivative or salt thereof |
WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
KR101072236B1 (ko) * | 2002-09-19 | 2011-10-12 | 아보트 러보러터리즈 | 디펩티딜 펩티다제-iv(dpp-iv)의 억제제로서의약제학적 조성물 |
US7390809B2 (en) * | 2002-10-07 | 2008-06-24 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes |
KR20050067418A (ko) * | 2002-10-18 | 2005-07-01 | 머크 앤드 캄파니 인코포레이티드 | 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제 |
PL376822A1 (pl) | 2002-11-07 | 2006-01-09 | Merck & Co., Inc. | Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy |
WO2004050022A2 (en) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US20060052382A1 (en) * | 2002-12-20 | 2006-03-09 | Duffy Joseph L | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
CA2512546A1 (en) * | 2003-01-17 | 2004-08-05 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2006516573A (ja) * | 2003-01-31 | 2006-07-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体 |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0308854D0 (en) * | 2003-04-16 | 2003-05-21 | Novartis Ag | Organic compounds |
PE20081293A1 (es) * | 2003-04-16 | 2008-11-04 | Novartis Ag | Procedimiento de preparacion de compuestos 2(s)-cianopirrolidina n-(n'-glicilo sustituida) |
EP1624874B1 (en) * | 2003-05-14 | 2009-11-04 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
EP1635818B1 (en) * | 2003-06-06 | 2010-04-07 | Merck Sharp & Dohme Corp. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004112701A2 (en) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
AU2004251829B2 (en) | 2003-06-20 | 2009-12-17 | F. Hoffmann-La Roche Ag | Hexahydropyridoisoqinolines as DPP-IV inhibitors |
KR100730867B1 (ko) | 2003-06-20 | 2007-06-20 | 에프. 호프만-라 로슈 아게 | Dpp-ⅳ 억제제로서의 피리도[2,1-a]이소퀴놀린 유도체 |
DE602004018503D1 (de) | 2003-07-31 | 2009-01-29 | Merck & Co Inc | Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
WO2005025554A2 (en) * | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Dipeptidyl peptidase iv inhibitor |
WO2005033099A2 (en) * | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
ZA200603165B (en) * | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
CN1870990A (zh) * | 2003-11-04 | 2006-11-29 | 默克公司 | 作为糖尿病治疗或预防用二肽基肽酶iv抑制剂的稠合苯基丙氨酸衍生物 |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
PT1689757E (pt) * | 2003-11-12 | 2014-12-09 | Sino Med Internat Alliance Inc | Compostos heterocíclicos de ácido borónico |
KR20150028829A (ko) | 2003-11-17 | 2015-03-16 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
ES2940341T3 (es) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulación y proceso de compresión directa |
EP1712547B1 (en) * | 2004-02-05 | 2011-12-14 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
EP1717225A4 (en) * | 2004-02-18 | 2009-10-21 | Kyorin Seiyaku Kk | BICYCLIC AMIDE DERIVATIVES |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
WO2005079795A2 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
US7514571B2 (en) * | 2004-02-27 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
EP1729774A4 (en) * | 2004-03-09 | 2009-05-06 | Nat Health Research Institutes | PYRROLIDINE COMPOUNDS |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
TW200604167A (en) * | 2004-04-27 | 2006-02-01 | Astellas Pharma Inc | Pyrrolidine derivatives |
AU2005241056A1 (en) * | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
CN1960990A (zh) * | 2004-05-18 | 2007-05-09 | 默克公司 | 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的环己基丙氨酸衍生物 |
JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
WO2005117861A1 (en) * | 2004-06-04 | 2005-12-15 | Novartis Ag | Use of organic compounds |
CA2573848A1 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ATE553077T1 (de) * | 2004-07-23 | 2012-04-15 | Nuada Llc | Peptidaseinhibitoren |
TW200608967A (en) | 2004-07-29 | 2006-03-16 | Sankyo Co | Pharmaceutical compositions containing with diabetic agent |
AR050615A1 (es) * | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
JP4959569B2 (ja) | 2004-10-12 | 2012-06-27 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス |
BRPI0518409A2 (pt) * | 2004-10-25 | 2008-11-18 | Novartis Ag | combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
CN101090888A (zh) | 2004-12-20 | 2007-12-19 | 霍夫曼-拉罗奇有限公司 | 4-氨基哌啶衍生物 |
US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
GT200600008A (es) * | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
WO2006090244A1 (en) * | 2005-02-22 | 2006-08-31 | Glenmark Pharmaceuticals S.A. | New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them |
TWI357902B (en) | 2005-04-01 | 2012-02-11 | Lg Life Science Ltd | Dipeptidyl peptidase-iv inhibiting compounds, meth |
ZA200708179B (en) * | 2005-04-22 | 2009-12-30 | Alantos Pharmaceuticals Holding Inc | Dipeptidyl peptidase-IV inhibitors |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
CA2610022A1 (en) | 2005-06-06 | 2006-12-14 | Georgetown University | Compositions and methods for lipo modeling |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
EP1912706A4 (en) * | 2005-06-17 | 2009-05-27 | Aurigene Discovery Technologie | NEW 5-SUBSTITUTED INDOL DERIVATIVES AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) HEMMER |
KR20080028422A (ko) * | 2005-07-12 | 2008-03-31 | 노파르티스 아게 | Dpp-iv 억제제 및 칸나비노이드 cb1 수용체길항제의 배합물 |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
MX2008001609A (es) * | 2005-08-04 | 2008-02-19 | Novartis Ag | Sales de vildagliptina. |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
DK1942898T4 (da) | 2005-09-14 | 2014-06-02 | Takeda Pharmaceutical | Dipeptidylpeptidase-inhibitorer til behandling af diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
CN101365476A (zh) * | 2005-10-07 | 2009-02-11 | 瓦拉塔药品公司 | Dpp-iv抑制剂和胃泌素化合物的联合使用 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
JP2009522374A (ja) * | 2006-01-06 | 2009-06-11 | ノバルティス アクチエンゲゼルシャフト | 糖尿病処置のためのビルダグリプチンの使用 |
CA2645154C (en) | 2006-03-08 | 2011-11-29 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
US20090186817A1 (en) | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
NZ571319A (en) * | 2006-04-03 | 2011-05-27 | Matrix Lab Ltd | Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them |
MX2008012756A (es) * | 2006-04-03 | 2009-03-05 | Matrix Lab Ltd | Inhibidores de dipeptidil peptidasa iv novedosos y procesos para su preparacion y composiciones farmaceuticas que los contienen. |
KR101281962B1 (ko) | 2006-04-11 | 2013-07-08 | 아레나 파마슈티칼스, 인크. | 특정 개체에게서 골 질량을 증가시키는 데에 유용한 화합물을 확인하기 위해 gpr119 수용체를 사용하는 방법 |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
PE20110235A1 (es) * | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
AU2007267833B2 (en) | 2006-05-26 | 2012-07-26 | Amylin Pharmaceuticals, Llc | Composition and methods for treatment of congestive heart failure |
EP2063890A1 (en) | 2006-09-07 | 2009-06-03 | Nycomed GmbH | Combination treatment for diabetes mellitus |
AU2007296556B2 (en) * | 2006-09-13 | 2013-09-19 | Takeda Pharmaceutical Company Limited | Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US20080167479A1 (en) * | 2007-01-10 | 2008-07-10 | Medichem, S.A. | Process for preparing vildagliptin |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
JPWO2008114857A1 (ja) | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
AU2008233548B2 (en) | 2007-04-03 | 2011-12-01 | Mitsubishi Tanabe Pharma Corporation | Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener |
DE102007022007A1 (de) * | 2007-05-08 | 2008-11-13 | Schebo Biotech Ag | Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes |
MX2009013354A (es) | 2007-06-04 | 2010-07-06 | Univ Ben Gurion | Compuestos de triarilo y composiciones que los contienen. |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
AU2008290582B2 (en) * | 2007-08-17 | 2014-08-14 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
WO2009037719A1 (en) * | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
US20090082420A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched vildagliptin |
WO2009042922A2 (en) * | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
JP5401465B2 (ja) * | 2007-11-30 | 2014-01-29 | ノバルティス アーゲー | 有機化合物 |
WO2009074829A1 (en) * | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
AU2008341352B2 (en) | 2007-12-21 | 2013-08-01 | Lg Chem, Ltd. | Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
WO2009155309A1 (en) * | 2008-06-19 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Substituted cyanopyrrolidine derivatives |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
CN102119139A (zh) | 2008-08-07 | 2011-07-06 | 杏林制药株式会社 | 二环[2.2.2]辛胺衍生物的制造方法 |
KR20110044780A (ko) * | 2008-08-14 | 2011-04-29 | 교린 세이야꾸 가부시키 가이샤 | 안정화된 의약 조성물 |
MX2011001525A (es) * | 2008-08-15 | 2011-03-29 | Boehringer Ingelheim Int | Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab. |
CZ2008512A3 (cs) | 2008-08-26 | 2010-03-10 | Zentiva, A. S | Zpusob prípravy vysoce cistého vildagliptinu |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
CN102850330B (zh) * | 2008-09-23 | 2014-10-15 | 成都地奥制药集团有限公司 | 经溴代的制备n取代的吡咯烷衍生物的方法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
SG172924A1 (en) | 2009-01-09 | 2011-08-29 | Orchid Res Lab Ltd | Dipeptidyl peptidase iv inhibitors |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
EP2395988A2 (en) | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
KR20120003906A (ko) | 2009-03-27 | 2012-01-11 | 교린 세이야꾸 가부시키 가이샤 | 염기성 첨가제를 함유하는 매트릭스형 서방성 제제 |
KR20120034639A (ko) | 2009-05-07 | 2012-04-12 | 아스트라제네카 아베 | 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750 |
BRPI1012852A2 (pt) | 2009-05-15 | 2018-06-19 | Novartis Ag | derivados de benzoxazolona como inibidores da sintase de aldoesterona |
SI2429995T1 (sl) | 2009-05-15 | 2014-05-30 | Novartis Ag | Arilpiridini kot inhibitorji aldosteron sintaze |
EP2435402B1 (en) | 2009-05-28 | 2016-04-13 | Novartis AG | Substituted aminobutyric derivatives as neprilysin inhibitors |
NZ596304A (en) | 2009-05-28 | 2014-01-31 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
US8748457B2 (en) | 2009-06-18 | 2014-06-10 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
EA034049B1 (ru) * | 2009-07-31 | 2019-12-23 | КРКА, д.д., НОВО МЕСТО | Гранулят, включающий вилдаглиптин, способ его получения и фармацевтическая композиция |
JP5734981B2 (ja) | 2009-09-02 | 2015-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼiv阻害剤としてのアミノテトラヒドロピラン |
JP5696856B2 (ja) | 2009-09-03 | 2015-04-08 | バイオエナジェニックス | Paskの阻害用複素環式化合物 |
CA2774015A1 (en) | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
EP2295083A1 (de) | 2009-09-15 | 2011-03-16 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin |
HUP0900638A2 (en) | 2009-10-07 | 2011-05-30 | Egyt Gyogyszervegyeszeti Gyar | Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions |
KR20120092629A (ko) | 2009-10-09 | 2012-08-21 | 아이알엠 엘엘씨 | Gpr119 활성의 조절제로서의 화합물 및 조성물 |
EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
EP2993169B1 (en) | 2009-11-17 | 2017-12-20 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
BR112012012210B8 (pt) | 2009-11-23 | 2021-05-25 | Cerulean Pharma Inc | conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
US8575160B2 (en) | 2009-11-30 | 2013-11-05 | Novartis Ag | Imidazole derivatives as aldosterone synthase inhibitors |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
WO2011078101A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | アダマンタンアミン誘導体 |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
CN101798270B (zh) * | 2010-02-25 | 2013-04-17 | 东华大学 | 一种3-氨基-1-金刚烷醇的制备方法 |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
CN102260265B (zh) | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
CN101870671B (zh) * | 2010-06-11 | 2012-06-27 | 漆又毛 | 金刚烷基吡咯烷衍生物及制备和应用 |
CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
IT1400714B1 (it) | 2010-07-06 | 2013-06-28 | Chemelectiva S R L | Processo ed intermedi per la preparazione di un principio attivo. |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
JP5812295B2 (ja) * | 2010-08-09 | 2015-11-11 | 塩野義製薬株式会社 | アミノアダマンタンカルバメート誘導体の製造方法 |
HU231050B1 (hu) | 2010-08-19 | 2020-02-28 | Egis Gyógyszergyár Nyrt. | Eljárás gyógyszerhatóanyag előállítására |
CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
TR201107482A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
TR201010683A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formülasyonları. |
EP2468268B1 (en) | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
TR201101809A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
CA2825456C (en) | 2011-01-31 | 2016-01-05 | Cadila Healthcare Limited | Treatment for lipodystrophy |
EP2681207B1 (en) | 2011-03-02 | 2016-12-28 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013006526A2 (en) | 2011-07-05 | 2013-01-10 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
EP2753328A1 (en) | 2011-09-07 | 2014-07-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
EP2572704A1 (en) | 2011-09-22 | 2013-03-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-Disintegrating Formulations of Vildagliptin |
ES2487271T3 (es) | 2011-10-06 | 2014-08-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulaciones de dosificación sólidas inhibidoras de DPP-IV |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
ITMI20112224A1 (it) | 2011-12-06 | 2013-06-07 | Chemelectiva S R L | Nuovo processo ed intermedi per la sintesi di vildagliptin |
CN102491928A (zh) * | 2011-12-13 | 2012-06-13 | 临海天宇药业有限公司 | 一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法 |
US9115082B2 (en) | 2012-01-18 | 2015-08-25 | Catherine Yang | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension |
WO2013122920A1 (en) | 2012-02-17 | 2013-08-22 | Merck Sharp & Dohme Corp. | Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CN102617434B (zh) * | 2012-03-29 | 2014-07-23 | 中国科学院上海有机化学研究所 | 一锅法制备维达列汀 |
WO2013179300A2 (en) | 2012-05-04 | 2013-12-05 | Megafine Pharma (P) Ltd. | A process for the preparation of vildagliptin and its intermediate thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
WO2014020462A1 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | Improved process for preparation of vildagliptin intermediate |
WO2014052619A1 (en) | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
CN103922986B (zh) * | 2013-01-16 | 2017-02-15 | 上海彩迩文生化科技有限公司 | 维大列汀及其类似物、中间体及其制备方法和应用 |
LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
CN105377246B (zh) | 2013-04-22 | 2018-03-20 | 卡迪拉保健有限公司 | 针对非酒精性脂肪性肝病(nafld)的新组合物 |
EP3004053B1 (en) | 2013-05-30 | 2021-03-24 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
CN103304502B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一类抗糖尿病化合物、其制备方法和用途 |
TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
KR20160031551A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
IN2013MU02470A (pt) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
MX2016001021A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Bioconjugados de polipeptidos de apelina sinteticos. |
WO2015033357A2 (en) | 2013-09-06 | 2015-03-12 | Cadila Healthcare Limited | An improved process for the preparation of pyrrole derivatives |
US10111880B2 (en) | 2013-11-05 | 2018-10-30 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
CN103641761A (zh) * | 2013-11-22 | 2014-03-19 | 沈阳化工大学 | 一种维格利汀的制备方法 |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
US20170014380A1 (en) | 2014-03-06 | 2017-01-19 | Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptin Formulation Process Under Inert Gas Atmosphere |
CN103992257B (zh) * | 2014-05-16 | 2016-03-30 | 苏州天马精细化学品股份有限公司 | 一种维格列汀粗品的纯化方法 |
CN105439873A (zh) * | 2014-08-20 | 2016-03-30 | 天津药物研究院 | 3-羟基-1-金刚烷胺的制备方法 |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
CN105884669B (zh) * | 2014-09-15 | 2020-05-15 | 深圳翰宇药业股份有限公司 | 制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法 |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CN104529857B (zh) * | 2015-01-13 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 卤代金刚烷酰胺类衍生物、其制备方法和用途 |
SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
CN104761456B (zh) * | 2015-03-10 | 2020-04-10 | 上海威智医药科技有限公司 | 3-氨基-1-金刚烷醇的制备方法 |
CN104817482B (zh) * | 2015-03-17 | 2017-05-10 | 宁波百思佳医药科技有限公司 | 2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用 |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
RU2628573C2 (ru) * | 2015-11-27 | 2017-08-21 | Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" | Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа |
BR112018013195A2 (pt) | 2015-12-28 | 2018-12-11 | Wockhardt Ltd | composição farmacêutica osmótica oral de vildagliptina |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
DE102016116130A1 (de) | 2016-08-30 | 2018-03-01 | Universität Bielefeld | Verfahren zur Herstellung chiraler Aminonitrile |
PL3512505T3 (pl) | 2016-09-16 | 2023-08-07 | Galenicum Health S.L.U. | Farmaceutyczne kompozycje wildagliptyny |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
BR112019011740A2 (pt) | 2016-12-09 | 2019-10-29 | Cadila Healthcare Ltd | composição farmacêutica e método para o tratamento de colangite biliar primária |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
GR1009406B (el) | 2017-10-03 | 2018-11-26 | Φαρματεν Αβεε | Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
KR102622198B1 (ko) | 2018-03-30 | 2024-01-09 | 한미약품 주식회사 | 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법 |
GR1009644B (el) | 2018-09-25 | 2019-11-12 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου |
CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽 |
WO2020110008A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
JP7461735B2 (ja) * | 2019-12-02 | 2024-04-04 | 日本ジェネリック株式会社 | ビルダグリプチン含有錠剤 |
CN113527167B (zh) * | 2020-04-14 | 2024-01-19 | 威智医药股份有限公司 | 一种维格列汀的生产方法 |
WO2021234430A1 (en) | 2020-05-17 | 2021-11-25 | Lotus International Pte. Ltd. | Modified release dosage form comprising vildagliptin and process for manufacturing the same |
WO2022003405A1 (en) | 2020-07-03 | 2022-01-06 | Savoi Guilherme | One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same |
US20230285576A1 (en) | 2020-08-05 | 2023-09-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
AU2022211069A1 (en) * | 2021-01-21 | 2023-07-27 | The Scripps Research Institute | Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE296075C (pt) * | ||||
DE158109C (pt) * | ||||
FR2572399B1 (fr) * | 1984-10-31 | 1987-01-16 | Panmedica Sa | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant |
US5118811A (en) * | 1989-04-13 | 1992-06-02 | Japan Tobacco Inc. | Amino acid derivatives possessing prolyl endopeptidase-inhibitory activities |
WO1991016339A1 (en) * | 1990-04-14 | 1991-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
ATE349461T1 (de) * | 1991-10-22 | 2007-01-15 | New England Medical Center Inc | Inhibitoren der dipeptidyl-aminopeptidase vom typ iv |
PH31294A (en) * | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
WO1995011689A1 (en) * | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
PL322706A1 (en) * | 1993-11-09 | 1998-02-16 | Merck & Co Inc | Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
FR2719049B1 (fr) * | 1994-04-22 | 1996-06-14 | Pasteur Institut | Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules. |
US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
EP0764151A2 (en) * | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
WO1999000008A1 (en) * | 1997-06-27 | 1999-01-07 | The Penn State Research Foundation | Agrobacterium-mediated transformation and efficient regeneration of cacao |
CA2819705C (en) * | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
JP2003190202A (ja) * | 2001-12-28 | 2003-07-08 | Yoshinobu Sekizawa | 使い捨てカイロ目的別貼付位置及び禁止位置表示付き下着 |
WO2003103550A2 (en) * | 2002-06-08 | 2003-12-18 | Ian Robert Thomson | Delivery system for a medicament or well-being enhancing composition |
-
1999
- 1999-12-02 CO CO99075802A patent/CO5150173A1/es unknown
- 1999-12-07 AR ARP990106231A patent/AR023719A1/es active IP Right Grant
- 1999-12-07 PE PE1999001213A patent/PE20001317A1/es not_active IP Right Cessation
- 1999-12-07 TW TW088121371A patent/TW509674B/zh active
- 1999-12-09 MY MYPI99005359A patent/MY123244A/en unknown
- 1999-12-09 TR TR2001/01478T patent/TR200101478T2/xx unknown
- 1999-12-09 BR BRPI9915985A patent/BRPI9915985B8/pt not_active IP Right Cessation
- 1999-12-09 PL PL348043A patent/PL199443B1/pl unknown
- 1999-12-09 IL IL14309199A patent/IL143091A0/xx active Protection Beyond IP Right Term
- 1999-12-09 RU RU2001118826/04A patent/RU2251544C2/ru active Protection Beyond IP Right Term
- 1999-12-09 CA CA002350609A patent/CA2350609C/en not_active Expired - Lifetime
- 1999-12-09 DE DE122008000017C patent/DE122008000017I1/de active Pending
- 1999-12-09 HU HU0104495A patent/HU226769B1/hu active Protection Beyond IP Right Term
- 1999-12-09 KR KR10-2001-7007227A patent/KR100509311B1/ko active IP Right Grant
- 1999-12-09 ES ES99959396T patent/ES2251847T3/es not_active Expired - Lifetime
- 1999-12-09 DK DK99959396T patent/DK1137635T3/da active
- 1999-12-09 SK SK789-2001A patent/SK286635B6/sk not_active IP Right Cessation
- 1999-12-09 WO PCT/EP1999/009708 patent/WO2000034241A1/en active IP Right Grant
- 1999-12-09 JP JP2000586689A patent/JP3681110B2/ja not_active Expired - Lifetime
- 1999-12-09 NZ NZ511935A patent/NZ511935A/en not_active IP Right Cessation
- 1999-12-09 CN CNB998142026A patent/CN1160330C/zh not_active Expired - Lifetime
- 1999-12-09 KR KR1020057007771A patent/KR20050047561A/ko not_active Application Discontinuation
- 1999-12-09 EP EP99959396A patent/EP1137635B1/en not_active Expired - Lifetime
- 1999-12-09 CZ CZ20012028A patent/CZ299151B6/cs not_active IP Right Cessation
- 1999-12-09 ID IDW00200101155A patent/ID28796A/id unknown
- 1999-12-09 AT AT99959396T patent/ATE307112T1/de active
- 1999-12-09 DE DE122008000007C patent/DE122008000007I1/de active Pending
- 1999-12-09 US US09/458,224 patent/US6166063A/en not_active Expired - Lifetime
- 1999-12-09 DE DE69927844T patent/DE69927844T2/de not_active Expired - Lifetime
- 1999-12-10 UY UY25843A patent/UY25843A1/es not_active IP Right Cessation
-
2001
- 2001-05-10 IL IL143091A patent/IL143091A/en active Protection Beyond IP Right Term
- 2001-06-05 ZA ZA200104581A patent/ZA200104581B/en unknown
- 2001-06-08 NO NO20012853A patent/NO318741B1/no not_active IP Right Cessation
-
2002
- 2002-01-28 HK HK02100662.5A patent/HK1040394B/zh not_active IP Right Cessation
-
2005
- 2005-01-17 JP JP2005008992A patent/JP2005112864A/ja active Pending
-
2006
- 2006-01-18 CY CY20061100065T patent/CY1105355T1/el unknown
-
2008
- 2008-01-16 LU LU91409C patent/LU91409I2/fr unknown
- 2008-01-17 NL NL300333C patent/NL300333I2/nl unknown
- 2008-01-23 FR FR08C0005C patent/FR08C0005I2/fr active Active
- 2008-01-25 CY CY200800002C patent/CY2008002I1/el unknown
- 2008-01-25 NO NO2008001C patent/NO2008001I1/no not_active IP Right Cessation
- 2008-05-09 NO NO2008004C patent/NO2008004I1/no unknown
- 2008-05-09 LU LU91435C patent/LU91435I2/fr unknown
- 2008-05-12 CY CY2008011C patent/CY2008011I2/el unknown
- 2008-05-14 NL NL300345C patent/NL300345I1/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9915985B1 (pt) | 2-cianopirrolidinas n-substituídas, composição farmacêutica que as compreende e uso das mesmas | |
EP0937040B1 (en) | N-substituted 2-cyanopyrrolidines | |
US6011155A (en) | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | |
US6107317A (en) | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | |
US6617340B1 (en) | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | |
US6110949A (en) | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | |
MXPA01005817A (en) | N-substituted 2-cyanopyrrolidines | |
MXPA99004281A (en) | N-substituted 2-cyanopyrrolidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15W | Others matters related to applications: legal action concerning application |
Free format text: INPI-52400.020973/2012 ORIGEM: JUIZO DA 008A VARA FEDERAL DE BRASILIA PROCESSO NO 59910-89.2011.4.01.3400 ACAO ORDINARIA DE NULIDADE DE ATO ADMINISTRATIVO, VISANDO ANULAR O ATO ADMINISTRATIVO PROFERIDO PELA ANVISA, QUE NEGOU A ANUENCIA PREVIA AUTOR: NOVARTIS AG (NOVARTIS SA)(NOVARTIS INC.) REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) |
Free format text: REQUERENTE DA NULIDADE: ASSOCIACAO DAS INDUSTRIAS DE QUIMICA FINA, E SUAS ESPECIALIDADES - ABIFINA - PETICAO NPRJ N.O 020140029155 DE 18/09/2014. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 09/12/2019 |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.006001/2022-52 ORIGEM: 21A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1023093-23.2022.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: NOVARTIS AG REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI |